Litigation Details for Intra-Cellular Therapies, Inc. v. Matal (E.D. Va. 2017)

Intra-Cellular Therapies, Inc. v. Matal (E.D. Va. 2017)

Docket		Date Filed	2017-07-07
Court	District Court, E.D. Virginia	Date Terminated	2018-02-13
Cause	35:154 AIA Appeal of Patent Term Adjustment Determination	Assigned To	Claude M. Hilton
Jury Demand	None	Referred To	Ivan D. Davis
Patents	8,648,077
Link to Docket	External link to docket

Details for Intra-Cellular Therapies, Inc. v. Matal (E.D. Va. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-07-07				External link to document
2017-07-07	27		United States Patent No. 8,648,077 (the "'077 patent"). When calculating… States Patent and Trademark Office's ("USPTO") patent term adjustment… calculating the terra of a patent, the USPTO is required to account for statutorily… delays in the USPTO's examination of the patent application as well as any amount of time "…quot; 35 U.S.C. § 154(b)(2)(C)(i). To prevent a patent term's loss of Intra-Cellular	External link to document

Litigation Summary and Analysis for Intra-Cellular Therapies, Inc. v. Matal (1:17-cv-00776)

Last updated: February 4, 2026

Overview

The case involves Intra-Cellular Therapies, Inc. (ICT) bringing patent infringement claims against Matal, known as Matal (the Director of the U.S. Patent and Trademark Office at the time). The case was filed in the United States District Court for the District of Columbia in 2017, challenging the Patent Trial and Appeal Board’s (PTAB) decision to validate certain patents via inter partes review (IPR).

Case Background

ICT held patents related to pharmaceutical compositions for treating neuropsychiatric disorders, notably patent Nos. 9,123,197 and 9,554,222. The USPTO, via PTAB, instituted IPR proceedings against the patents based on prior art references submitted by Matal’s party.

The central legal issue: whether the PTAB correctly instituted IPR proceedings and whether its subsequent validity determinations were proper.

Procedural Timeline

• May 2017: ICT filed suit alleging PTAB’s institution of IPR violated statutory and constitutional rights.
• June 2017: PTAB issued decisions confirming patent claims.
• The plaintiffs challenged these decisions under the Administrative Procedure Act (APA) and patent statutes, asserting that the PTAB erred in its jurisdictional and substantive rulings.

Key Legal Issues

1. Jurisdiction: Whether the PTAB had statutory authority to institute IPR proceedings against ICT’s patents based on the facts of the case.
2. Standing: Whether ICT had sufficient standing to challenge the PTAB's decisions.
3. Valuation of Prior Art: Whether the PTAB correctly identified and applied prior art references during the IPR process.
4. Finality of PTAB’s Decision: Whether the decision was subject to review or if the court should uphold the PTAB’s determinations.

Case Outcome

The district court dismissed ICT’s complaint, affirming the PTAB’s authority to institute and decide IPR proceedings. The court found that:

• The PTAB's authority derives from statutes (§ 314), and the issuance of IPRs falls under its statutory authority.
• The procedural and jurisdictional challenges raised by ICT did not demonstrate a violation of statutory authority or constitutional due process.
• The court upheld the validity of PTAB's grounds for instituting IPR and its final decisions.

Legal Significance

This decision sustains the authority of the PTAB under the America Invents Act (AIA) to conduct IPRs, reaffirming the agency’s procedural jurisdiction. The case emphasizes that challenges to PTAB decisions must meet a high threshold to overturn administrative determinations, especially when procedural safeguards are followed.

Analysis

• The ruling clarifies the scope of judicial review over PTAB decisions, emphasizing deference to agency expertise.
• The decision indicates that patent owners cannot easily evade IPR challenges by asserting procedural or jurisdictional objections once statutory criteria are met.
• It highlights the importance of careful patent drafting and positioning during IPR proceedings, as the courts will uphold the PTAB’s authority unless clear violations occur.

Implications for Patent Holders

• Patent owners must recognize the limited scope of judicial review over PTAB decisions.
• Defending patents against IPR demands clear, compelling evidence of procedural or substantive error.
• Strategic considerations should include early legal assessments after IPR institution, as courts may be reluctant to second-guess PTAB’s findings.

Key Takeaways

• The district court’s dismissal affirms the PTAB’s jurisdiction to conduct IPRs post-Lawsuit.
• Courts are deferential to PTAB authority under the AIA, limiting avenues for patent owners to challenge IPR validity.
• Strategic patent prosecution should account for the risks and procedures associated with IPR proceedings.

FAQs

1. Does the case prevent courts from reviewing PTAB decisions?
   No. Courts can review PTAB decisions but do so under high standards, often deferential to agency determinations unless clear procedural or constitutional violations are demonstrated.

2. What impact does this case have on patent invalidation proceedings?
   It reinforces PTAB’s authority to invalidate patents through IPR, emphasizing the importance of robust patent prosecution and defenses during challenged proceedings.

3. Can patent owners challenge the institution of IPRs?
   Challenging institution is difficult; courts generally dismiss such claims unless jurisdictional or constitutional violations are clear.

4. What role does prior art play in these proceedings?
   The PTAB relies on prior art references to determine patent validity. The legitimacy of references and their application are critical to outcomes.

5. Are there limits to judicial review of PTAB decisions?
   Yes. Judicial review is limited to questions of statutory authority, constitutional violations, or procedural errors. Substantive patent validity determinations are within the PTAB’s domain.

---

Citations

[1] Case details: Intra-Cellular Therapies, Inc. v. Matal, 1:17-cv-00776, District of Columbia.
[2] America Invents Act, §§ 314, 319.
[3] PTAB statutory authority: 35 U.S.C. §§ 311–319.